Product Description
Mechanisms of Action: TTR Inhibitor
Novel Mechanism: No
Modality: Nucleic Acid
Route of Administration: Subcutaneous
FDA Designation: *
Approval Status: Not Approved
Approved Countries: None
Approved Indications: None
Known Adverse Events: None
Company: Alnylam
Company Location: CAMBRIDGE MA 02142
Company CEO: Yvonne L. Greenstreet
Additional Commercial Interests: None
Clinical Description
Countries in Clinic:
Active Clinical Trial Count:
Recent & Upcoming Milestones
Highest Development Phases
Phase 3: Amyloid Neuropathies, Familial|Transthyretin Amyloidosis|Cardiomyopathies|Amyloidosis, Familial
Phase 2: Amyloidosis|Transthyretin Amyloidosis|Polyneuropathies|Amyloid Neuropathies, Familial|Amyloidosis, Familial
Phase 1: Amyloidosis
Trial |
Phase |
Trial Status |
Disease |
Primary Completion Date |
Probability of Success |
Latest Trial Update Date |
Data Updated |
|---|---|---|---|---|---|---|---|
| ALN-TTRSC-001 | P1 |
Completed |
Amyloidosis |
2015-04-01 |
2019-03-19 |
Treatments |
|
| ALN-TTRSC-003 | P2 |
Completed |
Amyloidosis |
2017-02-22 |
2019-03-20 |
Treatments |
|
| 2014-001229-34 | P2 |
Completed |
Transthyretin Amyloidosis |
2017-02-22 |
2022-03-13 |
Treatments |
|
| ALN-TTRSC-005 | P2 |
Completed |
Polyneuropathies|Amyloid Neuropathies, Familial|Transthyretin Amyloidosis|Amyloidosis, Familial |
2017-02-06 |
2019-03-29 |
Treatments |
|
| 2015-002603-29 | P2 |
Completed |
Transthyretin Amyloidosis |
2017-02-06 |
2022-03-13 |
Treatments |
|
| ALN-TTRSC-002 | P2 |
Completed |
Amyloidosis |
2014-10-01 |
2019-03-20 |
Treatments |
|
| ENDEAVOUR | P3 |
Completed |
Cardiomyopathies|Transthyretin Amyloidosis|Amyloidosis, Familial|Amyloid Neuropathies, Familial |
2017-03-30 |
2019-03-20 |
Treatments |
|
| 2014-003835-20 | P3 |
Completed |
Transthyretin Amyloidosis |
2017-03-30 |
2022-03-13 |
Treatments |
|
| 2015-005333-49 | P3 |
Terminated |
Transthyretin Amyloidosis |
2016-10-05 |
2022-03-13 |
Treatments |